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Neurobiology of Disease
Inhibition of the NFAT Pathway Alleviates Amyloid Beta
Neurotoxicity in a Mouse Model of Alzheimer’s Disease
Eloise Hudry,1Hai-YanWu,1Michal Arbel-Ornath,1 Tadafumi Hashimoto,1 RolandMatsouaka,2 Zhanyun Fan,1
Tara L. Spires-Jones,1 Rebecca A. Betensky,2 Brian J. Bacskai,1 and Bradley T. Hyman1
1Massachusetts General Hospital, Department of Neurology/Alzheimer’s Disease Research Laboratory, Charlestown, Massachusetts 02129, and 2Harvard
School of Public Health, Boston, Massachusetts 02115
Amyloid (A) peptides, themain pathological species associated with Alzheimer’s disease (AD), disturb intracellular calcium homeo-
stasis, which in turn activates the calcium-dependent phosphatase calcineurin (CaN). CaNactivation inducedbyA leads to pathological
morphological changes in neurons, and overexpression of constitutively active calcineurin is sufficient to generate a similar phenotype,
even without A. Here, we tested the hypothesis that calcineurin mediates neurodegenerative effects via activation of the nuclear
transcription factor of activated T-cells (NFAT). We found that both spine loss and dendritic branching simplification induced by A
exposure weremimicked by constitutively active NFAT, and abolished whenNFAT activation was blocked using the genetically encoded
inhibitorVIVIT.WhenVIVITwas specifically addressed to the nucleus, identical beneficial effectswere observed, thus enforcing the role
of NFAT transcriptional activity in A-related neurotoxicity. In vivo, when VIVIT or its nuclear counterpart were overexpressed in a
transgenicmodel of Alzheimer’s disease via a gene therapy approach, the spine loss andneuritic abnormalities observed in the vicinity of
amyloid plaques were blocked. Overall, these results suggest that NFAT/calcineurin transcriptional cascades contribute to A synapto-
toxicity, and may provide a new specific set of pathways for neuroprotective strategies.
Introduction
Amyloid  (A) soluble oligomers are thought to be an impor-
tant source of neurotoxicity in Alzheimer’s disease (AD) (Walsh
et al., 2002; Lesne´ et al., 2006; Shankar et al., 2007; Koffie et al.,
2009). While synaptic loss correlates best with cognitive decline
(Terry et al., 1991; DeKosky et al., 1996), the molecular mecha-
nisms underlying A synaptotoxicity and memory impairment
remain largely unexplained, and new therapeutic approaches act-
ing to protect neurons toward A-related injuries need to be
investigated.
Calciumdyshomeostasis and the consequent activation of cal-
cineurin (CaN, or protein phosphatase 2B) may trigger A-
related pathological effects (Liu et al., 2005; Shankar et al., 2007;
Kuchibhotla et al., 2008; Wu et al., 2010). An increased CaN
activity has been described in AD brains (Liu et al., 2005; Wu et
al., 2010), and CaN activation was reported in astrocytes sur-
rounding amyloid deposits, thus exacerbating neuroinflamma-
tion (Norris et al., 2005). In neurons, CaN activation leads to
pathological morphological changes, which could be blocked by
abolition of CaN enzymatic activity using FK506 (Wu et al., 2010;
Rozkalne et al., 2011). FK506 also improves cognitive deficits in
theTg2576ADmousemodel (Taglialatela et al., 2009), thusmak-
ing calcineurin a potential therapeutic target. However, because
FK506 prevents CaN phosphatase activity in all the cell types and
toward all its substrates, the mechanisms underlying FK506 neu-
roprotection are unclear.
Calcineurin is a unique neuronal Ca2/Calmodulin-dependent
serine/threonine phosphatase that plays fundamental physiolog-
ical roles during development and regulates processes such as
neurotransmitter release, synaptic plasticity, and learning (Klee
et al., 1979; Groth et al., 2003). Upon activation, CaN leads to
post-translational modification of postsynaptic proteins such as
cofilin (Zhou et al., 2004) and AKAP79, which is associated with
long-term depression (Bhattacharyya et al., 2009; Jurado et al.,
2010). In addition, CaN dephosphorylates the nuclear factor of
activated T cells (NFAT), which induces its nuclear translocation
and the expression of target genes implicated in neuronal sur-
vival, axonal outgrowth, and dendritic complexity (Benedito et
al., 2005; Nguyen and Di Giovanni, 2008; Schwartz et al., 2009).
CaN activation therefore triggers short-term effects directly at the
synapse as well as long-term modifications of synaptic plasticity
by modulating gene expression through NFAT.
To decipher more precisely the role of CaN activation in Alz-
heimer disease, we tested the hypothesis that neuronal morpho-
logical changes caused by Amay be improved by inhibiting the
CaN-induced NFAT pathway. We used a genetically encoded
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VIVIT peptide initially developed as a specific competitive inhib-
itor of the interaction between CaN andNFAT, without affecting
CaN phosphatase activity (Aramburu et al., 1999). We estab-
lished that (1) VIVIT efficiently inhibits the neurotoxic effects
associated with a constitutively activated CaN (CACaN); (2) ex-
pression of a constitutively active form of NFAT produces a phe-
nocopy of the effects induced by CACaN or by A exposure; (3)
A-induced decrease of spine density and dendritic complexity is
inhibited by VIVIT; (4) restricted expression of VIVIT in the
nucleus retains the beneficial effects of VIVIT, whereas a
membrane-bound version of this peptide has no effect; (5)
changes associated with amyloid plaques are alleviated when VI-
VIT or NLS-VIVIT were introduced by AAV-mediated gene de-
livery in the cortex of an AD mouse model in vivo.
Together, our findings offer new therapeutic opportunities by
targeting A downstream events through inhibition of NFAT
transcriptional pathways.
Materials andMethods
Culture of primary cortical neurons and collection of neuronal conditioned
media. Primary neurons were cultured from cerebral cortices of embry-
onic day 16 mice (Charles River Laboratories). Embryos resulted from
the mating between a Tg2576 male that heterozygously overexpresses a
humanmutatedAPP gene and awild-type female, thus giving rise to both
transgenic (Tg) and littermate (Wt) cultures. The genotype of each em-
bryo was determined by PCR. Neurons were prepared as previously de-
scribed (Wu et al., 2010) and plated to a density of 6.7  105 viable
cells/35mm culture dishes coated with poly-D-lysine (100g/ml, Sigma-
Aldrich). The medium of the cells was not renewed to allow A peptides
to accumulate and conditioned media were collected from 14 DIV cul-
tures (Wu et al., 2010). The concentration of A peptides was quantified
by a mouse/human ELISA kit (Wako) and reached 7000 pMol.
Transfection experiments were done at 5 DIV using Lipofectamine
2000 (Invitrogen).
Spine density and Sholl analyses. At 5 DIV, primary neurons were trans-
fected with either pEGFP-N1 or pDsRed-Express-N1 plasmids (Clontech
Laboratories), altogether with pVIVIT-EGFP and pVIVIT-NLS-EGFP con-
structs generously provided by Dr. Norris (Sanders-Brown Center On Ag-
ing, University of Kentucky, Lexington, KY) and Dr. Ruthazer (McGill
University, Montreal, QC, Canada), respectively. For a subset of experi-
ments, cells were also transfected with a wild-type or a constitutively active
form of calcineurin described previously (Wu et al., 2010). Live imaging of
GFP- or DsRed-expressing primary neurons (18 DIV) was used to analyze
the morphological parameters of the cells. Images of the whole cell and of
dendritic segments were captured using a LSM 510 Zeiss microscope to
determine the neuritic complexity and the spine density. GFP and DsRed
were respectively excited at 488 and 543 nm and emitted light was collected
between 500–550 nm and 565–615 nm. Dendritic spines were analyzed
using the NeuronStudio software (CNIC tools) that automatically detects
three different spine types (thin, stubby, andmushroom) according to their
morphological measures (i.e., length of the “neck” and size of the “head” of
each spine) (Rodriguez et al., 2008). The complexity of the neuronal den-
dritic tree was determined by Sholl analysis (Spires-Jones et al., 2011),
reporting the number of branch points with respect to the distance
from the cell body. All these parameters were evaluated on transfected
cells that did not show any obvious morphological alterations such as
dendritic dystrophies.
Immunocytochemistry. Immunostaining was performed using a stan-
dard protocol (Wu et al., 2010). Briefly, primary neurons were fixed with
4% paraformaldehyde in PBS, pH 7.4, for 15 min, permeabilized with
0.5%TritonX-100 in PBS for 20min, and blockedwith 3%bovine serum
albumin at room temperature for 1 h. Primary antibodies to detect
NFATc4 (polyclonal s.c.-13036, 1:200 dilution, Santa Cruz Biotechnol-
ogy), laminin-B1 (polyclonal ab16048, 1:1000, Abcam), HA tag (Clone
16B12, 1:200 dilution, Covance), and GFP (polyclonal ab6556, 1:1000,
Abcam or chicken anti-GFP, Aves) were incubated overnight at 4°C.
Secondary antibodies conjugated to either cyanine 3 (Cy3, 1:1000; Jack-
son ImmunoResearch), cyanine 5 (Cy3, 1:500; Jackson ImmunoRe-
search), or Alexa 488 (1:1000; Invitrogen, Eugene, OR) were then
applied. Fluorescent images were obtained using a LSM 510 Zeiss confo-
cal microscope.
Evaluation of NFAT subcellular localization. The changes in the subcel-
lular distribution ofNFATc4were evaluated after immunostaining of the
endogenous protein in primary neurons or in mouse brain slices. GFP-
positive neurons that were previously transfected or transduced with
GFP, VIVIT-GFP, or NLS-VIVIT-GFP were specifically analyzed. Using
ImageJ (National Institutes of Health open software), the fluorescence
intensity of NFATc4 in the nucleus was determined by overlap with the
nuclear staining DAPI (Vector Laboratories), whereas the fluorescence
intensity in the cytoplasm was quantified in the rest of the cell body,
excluding the nuclear compartment (Fig. 1C). The intensity of nuclear
NFATc4 was then divided by the intensity of cytoplasmic NFATc4.
Evaluation of NFAT transcriptional activity using a Luciferase reporter
system.Cortical primary neurons (7DIV)were transducedwith anAAV-
NFAT–TA–Luc, altogether with AAV-wtCaN or AAV-CACaN and
AAV-GFP, AAV-VIVIT-GFP, or AAV-NLS-VIVIT-GFP. Three days af-
ter transduction, cells were harvested and the luciferase activity wasmea-
sured with a luminometer using a reagent kit (Luciferase Assay System
with Reporter Lysis Buffer; Promega). The background luciferase activ-
ity, calculated when pNFAT-Luc alone was added, was subtracted from
all experiments.
Animals. In vivo experiments were performed using APPswe/PS1d9
double transgenic mice (APP/PS1, obtained from Jackson Laboratory)
that overexpress a human mutant amyloid precursor protein gene con-
taining the Swedish mutation K594N/M595L and a variant of the Prese-
nilin 1 gene deleted for the exon 9, both under the control of PrP
promoter (Jankowsky et al., 2004). Substantial amyloid deposition is
visible by 6 months of age and we used 7-month-old animals. Wild-type
littermates were used as controls. Experiments were performed in accor-
dance with NIH and institutional guidelines.
Viral vectors construction and production. Plasmids containing VIVIT-
GFP andNLS-VIVIT-GFPwere digested usingNotI andNcoI restriction
enzymes and subcloned into an AAV backbone containing the
chicken -actin promoter and a Woodchuck Hepatitis Virus Post-
Transcriptional Regulatory Element (WPRE). The Myr-tagged VIVIT-
GFP was obtained after amplification by PCR and insertion into an AAV
backbone using Xho1 and BsrG1 restriction sites. The AAV-NFAT–TA–
Luc plasmid was purchased from Clontech Laboratories and the con-
structions of AAV-CBA-HA-wtCaN and pAAV-CBA-HA-CACaN
backbones were described previously (Wu et al., 2010). As a control, we
used an AAV-GFP that was available at the Harvard Gene Therapy Core.
High titer of AAV serotype 2 vectors (AAV2-GFP, AAV2-VIVIT-GFP
andAAV2-NLS-VIVIT-GFP, AAV2-WtCaN,AAV2-CACaNandAAV2-
NFAT–TA–Luc) were produced after triple-transfection ofHEK293 cells
by the Harvard Gene Therapy Core, except for the AAV8-tdTomato that
was provided by the Gene Transfer Vector Core fromUniversity of Iowa,
Iowa City, IA. Lentiviral vectors coding forWtNFAT and CANFATwere
obtained after amplification of HA-mNFATc4 (WtNFAT) and HA-CA-
mNFATc4 (CANFAT) by PCR. Both PCR products were then digested
by NheI and BsrGI restriction enzymes and cloned into a pCSCW2-IRES
lentiviral backbone. Lentiviral vectors were produced by the Vector De-
velopment and Production Core at Massachusetts General Hospital. All
the constructs were verified by sequencing.
Stereotactic intracortical injections. Stereotactic intracortical injections of
AAVserotype2vectorswereperformedasdescribedpreviously (Spires et al.,
2005). Animals were anesthetized by intraperitoneal injection of ketamine/
xylazine (100 and 50 mg/kg body weight, respectively) and positioned on a
stereotactic frame (DavidKopf Instruments). Injections of vectorswere per-
formed in the cerebral cortex of each hemisphere with 3l of viral prepara-
tion (titer 2 1012 vg/ml) using a 33-gauge sharpmicropipette attached to
a 10 l Hamilton syringe (HamiltonMedical) at a rate of 0.12 l/min. Ste-
reotactic coordinates of injection siteswere calculated frombregma (antero-
posterior1mm,mediolateral 1mm, and dorsoventral1.2 mm).
Cranial window implantation and multiphoton imaging. Four weeks
after AAV intracortical injection, mice were anesthetized with isoflurane
(1.5%) and a cranial window was implanted by replacing a piece of skull
Hudry et al. • NFAT Inhibition Alleviates Amyloid Beta Toxicity J. Neurosci., February 29, 2012 • 32(9):3176–3192 • 3177
by a glass coverslip of 8 mm diameter [as described previously (Spires et
al., 2005)]. For imaging, a wax ring was built on the edge of the window
to create a well of water for the objective (Olympus XLPlan N 25
objective with a numerical aperture of 1.05). To visualize the amyloid
deposits, transgenic animals received an intraperitoneal injection of
methoxy-XO4 (5 mg/kg) 24 h before surgery, a fluorescent compound
that crosses the blood–brain barrier and binds to amyloid deposits (Bac-
skai et al., 2002; Klunk et al., 2002). When needed, Texas Red dextran
(70,000 Da molecular weight; 12.5 mg/ml in sterile PBS; Invitrogen) was
injected into a lateral tail vein to provide a fluorescent angiogram.
GFP-filled neuronal processes, amyloid deposits (in the case of
APP/PS1 animals), and blood vessels were imaged using the Olympus
FluoView FV1000MPE multiphoton laser-scanning system mounted
on an Olympus BX61WI microscope (Olympus). A DeepSee Mai Tai
Ti:sapphire mode-locked laser (Mai Tai; Spectra-Physics) generated
two-photon fluorescence with 860 nm excitation. Emitted light was
detected through three filters in the range of 420–460, 495–540, and
575–630 nm (Hamamatsu). Neurites were imaged at depth of 50–200
m from the surface of the brain. High-resolution images were cap-
tured using the optical zoom feature in the Fluoview software (63
63 1 m sections; 40–100 sections per stack).
Image processing and analysis. Two-dimensional projections of GFP-
filled neurites were obtained using ImageJ. Only dendrites that were at
least 20 m long and had prominent dendritic spine protrusions were
considered for analysis. Spine density and morphology were evaluated
using the NeuronStudio software, as described previously (Rodriguez et
Figure1. VIVIT-GFPoverexpressioncounteracts theeffectsof constitutivelyactivatedcalcineurin.A, RepresentativepicturesofGFP,NFATc4 immunostaining, andDAPI (top row) in cortical primaryneurons
transfectedwithWtCaNor CACaN, altogetherwith either GFP or VIVIT-GFP (transfected cells are indicated by an arrow). An increased colocalization of theNFATc4 immunostaining andDAPI is detected in cells
overexpressingCACaNandGFP(secondrow),which isabolishedwhenVIVIT-GFP is cotransfected.Thebottomrowrepresents thedetectionofNFATc4 immunostaining in thenucleusand in thecytoplasmusing
ImageJ.Scalebar,50m.B,NFATc4ratiosbetweenthenucleusandthecytoplasmaresignificantly increasedwhenCACaNisoverexpressedcomparedwithGFPandWtCaNGFP.WhenCACaNisco-transfected
with VIVIT-GFP, the nucleus/cytoplasm ratios are significantly decreased and become comparable to neurons transfected with WtCaNGFP. C, Analysis of NFAT transcriptional activity using the Luciferase
reporter system shows that overexpression of CACaN leads to a significant higher Luciferase signal (i.e., higher NFAT transcriptional activity) compared with WtCaN and CACaNVIVIT. D, E, Representative
images and spine density quantification of neurons transfected with GFP, WtCaN/GFP, CACaN/GFP, or CACaN/VIVIT-GFP show that cells co-transfected with CACaN and GFP have a decreased spine density
comparedwith GFP orWtCaNGFP overexpressing neurons, which is significantly increased by VIVIT-GFP. Scale bar, 100m. F, The proportion of each spine type is also affected by CACaN and a significant
decreaseof themoremature “mushroom” spines is observed comparedwithGFPandWtCaN/GFP transfectedneurons. This effect is greatly abolishedwhenVIVIT-GFP is overexpressed.G, Theoverall dendritic
complexity isalso improvedwhentheVIVIT inhibitorwascoexpressedwithCACaNcomparedwithCACaN/GFPtransfectedcells.Nostatisticaldifference isobservedbetweenGFP,WtCaN/GFP,andCACaN/VIVIT-
GFP transfected cells. *p 0.05, **p 0.001 and ***p 105. (n 40 cells per condition).
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al., 2008). Distances to plaques were evaluated by the average of three
different measures between each neurite (twomeasures at each endpoint
and one measure at the midpoint) and the edge of the nearest amyloid
deposit.
Immunohistological analysis.Onemonth after implantation of the cra-
nial window, mice were killed by CO2 inhalation. One cerebral hemi-
sphere was fixed in 4% paraformaldehyde in PBS whereas the other
hemisphere was snap frozen in liquid nitrogen. To detect GFP and
NFATc4, paraffin-embedded sections (10 m) were sequentially depar-
affinized in xylene, rehydrated in ethanol, treated in citrate buffer (10mM
Sodium Citrate, 0.05% Tween 20, pH 6.0), permeabilized in PBS with
0.5%Triton, blocked in PBSwith 3%BSA, and incubated overnight with
the primary antibody. Incubation with the secondary antibody was done
for 2 h at room temperature the next day.
Statistical analysis. Except for the Sholl’s plot analyses, statistical anal-
yses were done using Statview and JMP softwares. In vitro experiments
were done at least in triplicate. In vivo, at least five animals were included
per condition. Equality of variances (F test) was verified between each
date of experiment and between animals of the same group. We made
comparisons between groups by one- or two-way ANOVA followed by
post hoc Bonferroni correction for multiple comparisons among means.
Data are presented as meanSD.
Sholl’s plot analyses were represented as the mean of the number of
intersections according to the distance from the cell body, and statistics
were done using a newly developed analytical approach [usingR software
(Spires-Jones et al., 2011)]. To assess the difference in length and com-
plexity of dendritic arborization between each treatment, the area under
the curve (AUC) was estimated through a trapezoidal method, which
reflects the overall complexity of the dendritic arborization. AWilcoxon
rank sum test followedby aBonferroni p value adjustment procedurewas
applied. For all the analyses, differences with a p value of 0.05 were
considered statistically significant.
Results
Genetically encoded VIVIT blocks NFAT accumulation in the
nucleus and prevents spine loss and dendritic simplification
induced by constitutively active calcineurin (CaN)
The use of pharmacological inhibitors of CaN phosphatase activ-
ity, such as FK506, is associated with a broad range of side-effects
in transplanted patients (Ponticelli and Campise, 2005; Lee et al.,
2008). In an effort to develop a safer drug, Aramburu et al. (1999)
screened for anNFAT-specific reagent and developed a new inhibi-
tor peptide called VIVIT (16 aa, MAGPHPVIVITGPHEE) that was
able to interact with the CaN docking motif of NFAT with a high
affinity, without interfering with its enzymatic activity.
In vitro, we first tested whether the overexpression of VIVIT-
GFP in cortical primary neurons was able to counteract the nu-
clear translocation and the transcriptional activity of NFATc4
[the most prominent NFAT isoform in neurons (Ho et al.,
1994)], as well as the neuronal morphological changes induced
by a constitutively active form of calcineurin (CACaN). The con-
stitutively active CaN was initially identified as a calpain-
dependent truncated product of calcineurin (45 kDa), in which
the regulatory autoinhibitory domain was removed, so that CA-
CaN has an enhanced phosphatase activity (Wu et al., 2004). By
contrast, overexpression of wild-type calcineurin (WtCaN) is
tightly regulated and does not lead to an increase of calcineurin
activity. At 5 DIV, cortical primary neurons were cotransfected
with either CACaN or WtCaN and with either GFP or VIVIT-
GFP. Cells were cultured for 16–18 DIV before analysis. Because
of the presence of an HA-tag in the WtCaN and CACaN con-
structs, we verified that 90% of GFP-filled neurons also coex-
pressed each form of CaN (data not shown). As expected, the
nuclear/cytoplasmic ratio of NFATc4 immunofluorescence in-
tensity was significantly higher when CACaN was overexpressed
(0.94  0.025) compared with WtCaN (0.62  0.028), whereas
WtCaN by itself did not affect NFAT subcellular localization
compared with GFP transfected cells (0.67  0.08) (Fig. 1A,B).
This suggests that increased CaN activity leads to an accumula-
tion of NFATc4 in the nucleus. By contrast, co-transfection of
CACaN with VIVIT-GFP prevents the nuclear accumulation of
NFATc4, as indicated by lower nuclear/cytoplasmic ratios
(0.62 0.036) that were comparable toWtCaN transfected neu-
rons (Fig. 1A,B).When VIVIT-GFP alone was overexpressed, no
change could be detected in the subcellular localization of
NFATc4 and the nuclear/cytoplasmic ratio remained comparable
to GFP-transfected cells (data not shown). To further evaluate
the effect of VIVIT on NFAT transcriptional activity, a reporter
system containing several NFAT transcriptional response ele-
ments driving the expression of luciferase was used. Primary neu-
rons were transduced with AAV-GFP, AAV-WtCaNGFP,
AAV-CACaNAAV-GFP, AAV-CACaNAAV-VIVIT-GFP at
10DIV, and luciferase activitywas quantified after 3 d.Overexpres-
sionof a constitutively active formof calcineurin led toan increaseof
NFAT transcriptional activity compared with WtCaN. When
VIVIT-GFP was co-transduced with CACaN, a significant decrease
of the Luciferase activity was observed, suggesting that VIVIT effi-
ciently inhibits NFAT-dependent transcriptional activity (Fig. 1C).
To determine whether VIVIT-GFP was able to prevent the
pathological morphological changes induced by CACaN, we an-
alyzed the spine density and dendritic complexity of GFP or
VIVIT-GFP-expressing neurons that were also transfected with
WtCaN or CACaN plasmids. The density of spines in CACaN/
GFP overexpressing neurons (0.18 0.046 spines/m) was sig-
nificantly lower comparedwith cells overexpressingWtCaN/GFP
(0.42  0.09 spines/m; Fig. 1D,E). Sholl’s plot analyses also
indicated that uncontrolled activation of calcineurin in neurons
induced a marked dendritic simplification compared with wild-
type calcineurin (Fig. 1D,G). However, when VIVIT-GFP was
introduced together with CACaN, a significantly higher spine
density (0.4  0.081 spines/m) and a more complex neuritic
arborization were observed, so that these morphological param-
eters reached those of WtCaN transfected neurons (Fig. 1D,E,
G). Importantly, no difference was observed between cells that
were transfected with GFP alone (0.43  0.13 spines/m) or
WtCaNGFP (0.42 0.09 spines/m), suggesting that WtCaN
did not change the spine density and dendritic complexity of
cortical neurons in culture (Fig. 1D,E,G). Similarly, overexpres-
sion of VIVIT-GFP alone did not affect the morphological pa-
rameters of the cells (data not shown). The beneficial effect of
VIVIT-GFP was therefore specifically related to the inhibition of
CACaN-dependent NFAT activation.
Interestingly, when the different spine types were compared, a
decreased proportion of “mushroom” type spines was associated
with CACaNGFP (38% 1.8%) compared with GFP (47%
2.8%), WTCaNGFP (44%  2.3%), or CACaNVIVIT-GFP
(46% 1.4%) (Fig. 1F), implicating calcineurin activation in the
collapse of mature, mushroom-shaped spines that are known to
be more stable than thin spines (Holtmaat et al., 2005).
Constitutively active NFAT induces morphological
abnormalities in primary neurons that phenocopy the
effects of constitutively active CaN
As both spine loss and dendritic simplification were rescued
when a genetically encoded VIVIT-GFP was overexpressed in
neurons, we postulated that the morphological effects of
CACaN were related to NFAT activation. We therefore inves-
tigated the specific effects of NFATc4 on these morphological
parameters. We transduced 14 DIV cortical neurons with ei-
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ther a lentiviral vector encoding a HA-tagged wild-type
(WtNFAT) or constitutively activated (CANFAT) form of
NFATc4 that lacks its N terminus regulatory CaN binding
domain. This truncated NFATc4 is therefore activated with-
out calcineurin (Molkentin et al., 1998). To detect morpho-
logical variables, neurons were previously transfected with
GFP at 5 DIV and we verified that a high percentage (80%) of
the GFP-filled cells were also positive for HA. As observed in
Figure 2A, WtNFAT was mainly detected in the cytoplasm and
was excluded from the nucleus (delimited by the marker of
the nuclear membrane laminin-B1), whereas, as expected, the
constitutively active form of NFATc4 was concentrated in the
nucleus. Importantly, CaN activity was not previously in-
duced in these cells (either by using a calcium ionophore or
CACaN overexpression), demonstrating that CANFAT did
not depend upon any other upstream events to be activated. In
contrast to CACaN-induced NFATc4 nuclear recruitment, ac-
cumulation of CANFAT into the nucleus could not be pre-
vented by VIVIT-GFP (Fig. 2A). Overexpression of CANFAT
led to a significant decrease of spine density (0.22  0.045
spines/m) and dendritic simplification compared with Wt-
NFAT (0.39  0.07 spines/m). None of these changes could
be improved by co-transfection with VIVIT-GFP (0.24 
0.023 spines/m) (Fig. 2B–D), thus demonstrating that
VIVIT acts upstream of NFAT activation and does not have an
effect nonrelated to calcineurin. We therefore concluded that
ectopic expression of a constitutively active form of NFATc4 is
sufficient to induce spine loss and dendritic simplification in
primary neurons, suggesting that NFATc4-related transcrip-
tional events are critical for CaN-induced neurotoxicity in vitro.
Figure 2. Overexpression of a constitutively activated NFATc4 is sufficient to induce abnormal morphological changes in primary neurons. A, Representative images of the nuclear membrane
marker lamininB1 andofHA-taggedNFATc4 in cortical neurons thatwere transducedwithWtNFAT/CANFAT (lentiviral vectors).WtNFAT (left) ismainly present in the cytoplasm, outside thenucleus
delimited by laminin B1. On the contrary, the constitutively activated formofNFATc4was concentrated into the nucleus of the cells and fit the laminin B1 staining. The nuclear localization of CANFAT
is not affected by the overexpression of VIVIT-GFP (right). Scale bar, 10m.B, Images of GFP-filled neurons (top) and dendrites (bottom) thatwere transducedwith eitherWtNFAT or CANFAT. Scale
bar, 100m. C, Overexpression of CANFAT is associated with a decreased number of spines per dendritic segment compared withWtNFAT transduced cells. The loss of dendritic spines observed in
CANFAT-expressing neurons is not improved by VIVIT-GFP. D, The overall dendritic complexity is also decreased by CANFAT compared with WtNFAT. The lower dendritic complexity induced by
CANFAT cannot be rescued by VIVIT-GFP ( p 0.18 when compared with CANFAT/GFP transfected cells). *p 0.05 and **p 0.01. (n 30 cells per condition).
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Overexpression of VIVIT in Tg2576 transgenic neurons or in
wild-type neurons treated with A-containing medium
rescues their morphological abnormalities
We previously observed that both transgenic neurons cultured
from Tg2576 embryos and wild-type neurons treated with A-
containing conditioned media develop AD-like pathological
morphological changes that include dendritic spine loss and neu-
ritic simplification. The involvement of CaN in these processes
was suggested by the fact that both phenotypes could be rescued
when FK506was added to themediumor used in transgenicmice
(Wu et al., 2010; Rozkalne et al., 2011). Here we showed that the
overexpression of constitutively activated CaN or NFAT pheno-
copy the morphological changes induced by A. Based on these
observations, we asked whether the inhibition of NFAT activa-
tion by calcineurin can also alleviate A synaptotoxicity.
We first tested the efficiency of VIVIT-GFP in transgenic
neurons that were cultured from Tg2576 embryos. Because the
mutated APP transgene was present as a heterozygous state,
transgenic (Tg) or littermate (Wt) cultures could be analyzed
in parallel. Cells were transfected with either GFP or VIVIT-
GFP at 5 DIV and analyzed at 18 DIV. A decreased density of
dendritic spines was observed in Tg neurons (0.21  0.11
spines/m) compared with their wild-type counterpart
(0.45 0.1 spines/m) (Fig. 3A,B). The spine loss detected in
Tg neurons was also associated with a simplification of the
dendritic tree (Fig. 3C). Importantly, when VIVIT-GFP was
overexpressed in Tg neurons, both parameters were rescued to
normal wild-type levels (spine density: 0.39  0.12 spines/
m) and significantly improved compared with Tg neurons
transfected with GFP alone.
To study the effect of exogenous A peptides on neuronal
morphological parameters, A-containing conditioned medium
(TgCM) was obtained by collecting the medium of Tg neurons
after 2weeks in culture andused to treat naivewild-type cells. The
concentration of A40 was estimated as 7000 pM and was compa-
rable to the levels observed in AD brains (Ingelsson et al., 2004).
Western blot analysis showed that TgCM mainly contained sol-
uble oligomeric species (data not shown) that have been de-
scribed to have important neurotoxic effects (Walsh et al., 2002;
Lesne´ et al., 2006; Shankar et al., 2007, 2008). Wild-type primary
neurons cultured in standard NB/B27-serum free medium for 16
DIV were exposed for 24 h to either wild-type (WtCM) or trans-
genic (TgCM) conditioned media diluted 1:1 in the initial me-
dium. As observed in Figure 3,D and E, 24 h exposure to Awas
sufficient to induce a significant loss of spines in wild-type pri-
mary neurons (0.28 0.075 spines/m) compared with WtCM
treatment (0.48  0.12 spines/m). However, no change of the
dendritic complexity was observed, suggesting that such a short
exposure with oligomeric A could not affect the whole dendritic
arbor of the cells. A immunodepletion (using the anti-
amyloid- monoclonal antibody 6E10) significantly inhibited
the effect of TgCM on spines (0.39  0.09 spines/m), demon-
strating that the spine loss was directly related to the presence of
amyloid  species (immunodepletion led to a 70% decrease in
TgCMA content). Remarkably, when cortical primary neurons
were transfected with VIVIT-GFP, before exposure to TgCM, the
effect on spine density was greatly ameliorated (0.41  0.108
spines/m), despite the persistence of A species in themedium.
This suggests that blocking CaN-mediated activation of NFAT
protects against neurotoxic effects of soluble exogenous A
oligomers.
A nuclear-targeted form of VIVIT, but not a membrane
bound VIVIT, is a potent inhibitor of CaN-induced
morphological changes in primary neurons
VIVIT was initially identified as a selective blocker of the CaN/
NFAT interaction, mimicking the PxIxIT sequence of NFAT that
is required to bind calcineurin. Although Aramburu et al. (1999)
showed that calcineurin activity on critical substrates (such as
CREB) was not affected by VIVIT, several recent studies sug-
gested that it can also disrupt the interaction between CaN and
other important cytosolic targets implicated in the regulation of
synaptic activity such as AKAP or cabin (Dell’Acqua et al., 2002;
Liu, 2003). In an attempt to precisely decipher the role of the
transcription factor NFAT in A-related neurotoxic events, we
used a nuclear-targeted version of VIVIT that was shown to have
a restricted localization within the nucleus and that was previ-
ously used to specifically counteract NFATc4-related transcrip-
tional activity (Schwartz et al., 2009). As a negative control, we
fused a myristoylation (Myr) tag to the VIVIT-GFP plasmid to
direct the localization of this peptide toward the cell membrane.
Thus, these constructs would disambiguate the transcriptional
effects of VIVIT from other non-transcriptional functions at the
spines.
We first tested whether these two constructs, NLS-VIVIT-
GFP and Myr-VIVIT-GFP, showed the expected subcellular lo-
calization. At 5 DIV, primary cortical neurons were transfected
with GFP, NLS-VIVIT-GFP, orMyr-VIVIT-GFP. As observed in
Figure 4A, NLS-VIVIT-GFP was strictly restricted to the nuclear
compartment and limited by the nuclear membrane marker
laminin B1. By contrast, the fluorescent signal of Myr-VIVIT-
GFPwas completely excluded from the nucleus.When each plas-
mid was transfected altogether with DsRed (as a common
denominator to obtain the full morphology of each cell), both
GFP and Myr-VIVIT-GFP could be detected in the processes of
neurons and in the dendritic spines, which was not the case for
NLS-VIVIT-GFP (Fig. 4B).
Todetermine theeffectofNLS-VIVITandMyr-VIVITonNFAT
transcriptional activity, primary neurons were transduced with
an AAV-pNFAT-Luc reporter vector, altogether with AAV-
WtCaNGFP, AAV-CACaNAAV-GFP, AAV-CACaNAAV-
NLS-VIVIT-GFP, or AAV-CACaNAAV-Myr-VIVIT-GFP. After
3 d, the luciferase activity was quantified. As previously observed,
overexpression of a constitutively active form of calcineurin led
to an increase of NFAT transcriptional activity compared with
WtCaN. This increase was significantly diminished when NLS-
VIVIT-GFP was overexpressed, but no change could be detected
with Myr-VIVIT-GFP. This suggested that only a nuclear-
targeted inhibitor was able to inhibit NFAT transcriptional activ-
ity in vitro (Fig. 5A). We next determined whether CaN-induced
morphological changes could be rescued by the different VIVIT-
GFP constructs by co-transfecting neuronal cultures with either
WtCaN or CACaN, altogether with GFP, NLS-VIVIT-GFP, or
Myr-VIVIT-GFP. Because dendrites and spines were not detect-
able from the GFP signal when NLS-VIVIT-GFP was overex-
pressed, we used DsRed as a common denominator to evaluate
spine density and dendritic complexity. At 18 DIV, both spine
loss and dendritic simplification associated with CACaN overex-
pression were significantly improved whenNLS-VIVIT-GFPwas
transfected (Fig. 5B–D). By contrast, no effect could be detected
when Myr-VIVIT-GFP was used, consistent with the hypothesis
that the neuroprotection of VIVIT against CACaN-mediated
neurodegeneration is related to transcriptional effects in the nu-
cleus rather than non-transcriptional effects in the cytoplasm or
dendrites.
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Figure 3. Themorphological abnormalities observed in Tg neurons and in TgCM-treated neurons are improved by VIVIT-GFP. A, Representative images of Wt and Tg GFP-labeled neurons (left)
and dendrites (right) at 18 DIV. Scale bar, 100m. B, GFP-transfected Tg neurons present a lower spine density comparedwithWt littermate cells, but the number of spines is (Figure legend continues.)
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Nuclear-targeted VIVIT, but not membrane-targeted VIVIT,
protects against A neurotoxicity in primary neurons
In the previous experiment, we determined that a nuclear version of
VIVIT was almost as potent as a nontargeted VIVIT at blocking the
pathological changes induced by CACaN. Considering the fact that
calcium dyshomeostasis and CaN activation have been shown to be
downstream events to A neurotoxicity (Busche et al., 2008;
Kuchibhotla et al., 2008), we next asked whether a nuclear-targeted
version of this peptidemay be protective against A toxicity as well.
Following the same procedures as described above, we tested the
NLS-VIVIT-GFP orMyr-VIVIT-GFP constructs inWt and Tg pri-
mary neurons that were co-transfected with DsRed (Fig. 6A). Both
spine density and dendritic complexity were significantly improved
when NLS-VIVIT-GFP was overexpressed in Tg neurons, but no
improvement was detected withMyr-VIVIT-GFP (Fig. 6B,C).
Similarly, when Wt primary neurons were transfected with
GFPDsRed, NLS-VIVIT-GFPDsRed, or Myr-VIVIT-GFP
DsRed and then treated for 24 h with A-containing TgCM (Fig.
6D), the TgCM-induced spine loss was attenuated by NLS-VIVIT-
GFP (Fig. 6E), but no change could be observed in TgCM-treated
neurons transfected with GFP or Myr-VIVIT-GFP. Again, this
short-term exposure to A oligomers did not affect the dendritic
branching of the cortical neurons (data not shown).
Together, these observations strongly suggest that NFAT-related
transcriptional events play a role in A-related neurotoxicity, thus
predicting that inhibition of the CaN/NFAT pathwaymay be a pro-
tective strategy against A-induced neuronal injuries in vivo.
4
(Figure legend continued.) significantly improvedwhen Tg neuronswere previously transfected
with VIVIT-GFP. C, In addition, Sholl’s plot analyses ofWt and Tg cultures show an overall decreased
complexity of the dendritic arborization in Tg neurons overexpressing GFP compared with Wt neu-
rons. The simplification of the dendritic arbor is fully correctedwhen Tg neuronswere transfected by
VIVIT-GFPand it reaches the level of complexity observed inWtneurons (pNScomparedwithWt
neurons transfected with GFP). D, Representative images of wild-type cortical neurons (left) and
dendrites (right) expressingGFPorVIVIT-GFPafter treatment for 24hwithWtCM, TgCM,ordepleted
TgCM. Scale bar, 100m. E, Dendritic spine quantification demonstrates that a short exposure to
oligomeric A leads to a significant decrease of their density, whereas spines are unaffected when
WtCMwas applied. However, the spine density is maintained when TgCM-treated neurons overex-
press VIVIT-GFPorwhenApeptideswerepreviously immunodepleted from themediumusing the
6E10 antibody. *p 0.01, **p 0.0001 and ***p 1010. (n 40 cells per condition).
Figure 4. NLS-VIVIT-GFP localization is restricted to the nucleus,whereasMyr-VIVIT-GFP is excluded from this compartment.A, Representative images of primary neurons thatwere transfectedwith GFP,
NLS-VIVIT-GFP, orMyr-VIVIT-GFPand then stained for lamininB1andDAPI (left). On the right, highermagnification images showthatGFPalone canbedetected in thenuclear andcytoplasmic compartments,
whereasNLS-VIVIT-GFP is surroundedby laminin B1 and colocalizeswithDAPI, suggesting that it is restricted to the nucleus. Inversely,Myr-VIVIT-GFP is excluded from the nuclear compartment. Scale bar, 50
m.B, BothGFPandMyr-VIVIT-GFPcanbedetected in thedendritic shaft and in spines, as suggestingby the colocalizationwithDsRed.NLS-VIVIT-GFP is, however, absent in theneuronalprocesses. Scalebar,
100m.
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Disruption of NFAT pathway with VIVIT and NLS-VIVIT
increases spine density in the vicinity of amyloid plaques
in vivo
In vitro, we observed that a selective disruption of the interac-
tion between CaN and NFAT may alleviate A-related neuro-
toxicity. We asked whether these neuroprotective effects could
be reproduced in vivo. Neurites surrounding amyloid deposits
have an increased calcium overload, decreased spine density,
and an increased probability to develop neuritic dystrophies
(Spires et al., 2005; Kuchibhotla et al., 2008). Interestingly,
overexpression of a constitutively activated CaN in vivo leads
to similar abnormal neuronal changes (Wu et al., 2010). We
therefore hypothesized that amyloid aggregates may be re-
sponsible for an abnormal increased activation of CaN/NFAT
pathway in vivo, which would compromise neuronal integrity.
We revisited this hypothesis by delivering VIVIT in the brains
Figure5. The restricted localization of VIVIT into the nucleus potently inhibits themorphological abnormalities induced by an overactivated formof CaN.A, NFAT transcriptional activity assessed
using the pNFAT-luciferase reporter system shows that overexpression of NLS-VIVIT-GFP, altogether with CACaN, is associated with a decreased luciferase activity. No effect is observed when
Myr-VIVIT-GFP is overexpressed, suggesting that this inhibitor does not affect NFAT transcriptional activity. B, Representative images of cortical primary neurons (top) and dendrites (bottom) that
were co-transfected with GFP, NLS-VIVIT-GFP, andMyr-VIVIT-GFP altogether with CACaN andWtCaN. To be able to observe the neurites and quantify the dendritic spines in all the conditions, cells
were co-transfected with a DsRed fluorescent reporter. Scale bar, 100 m. C, The decreased spine density associated with the overexpression of a constitutively activated CaN (CACaN) can be
improved by co-transfection with a nuclear-targeted VIVIT (NLS-VIVIT-GFP), whereas no beneficial effects is observed with a membrane-bound VIVIT. D, Overexpression of NLS-VIVIT also leads to
a more complex dendritic arborization of CACaN transfected neurons, whereas overexpression of Myr-VIVIT cannot rescue the effects of CACaN. *p 0.05. (n 30 cells per condition).
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Figure 6. Aberrant neuronal morphology observed in Tg neurons and in TgCM-treated cells are prevented by NLS-VIVIT-GFP but not byMyr-VIVIT-GFP. A, Representative images of DsRed-filled
Wt or Tg neurons (left) and dendrites (right) overexpressing GFP or the different VIVIT constructs show that Tg cells transfected by NLS-VIVIT-GFP present an increased spine density comparedwith
GFP transfected Tg cells. Scale bar, 100m.B, Bar graph summarizing the averaged spine density of each group confirms that only the nuclear targeted peptide is able to improve themorphological
abnormalitiesobservedinTgneurons,butthis isnotthecasewhenMyr-VIVIT-GFPisoverexpressed.C,Sholl’splotanalysisdemonstratesthatNLS-VIVIT-GFPalsoincreasesthedendritic(Figurelegendcontinues.)
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of APP/PS1 transgenic mice and exam-
ining its effects on neuritic
degeneration.
To investigate the effect of VIVIT in
vivo, AAV vectors encoding for VIVIT-
GFP, NLS-VIVIT-GFP (both inhibitors
having proven beneficial effects in vitro),
and GFP (as a control) were stereotacti-
cally injected in the cortex of 7-month-old
littermates or APP/PS1 mice, when amy-
loid deposits are already present. In the
case of AAV-NLS-VIVIT-GFP injected
mice, we first verified that the recombi-
nant protein was properly addressed to
the nuclear compartment and colocalized
with Hoechst-stained nuclei (Hoechst so-
lution was applied topically; Fig. 7A).
AAV-NLS-VIVIT-GFP and AAV-GFP
were then coinjected with a ratio of 3:1, so
that a high proportion of GFP filled neu-
rons were also transduced by the AAV-
NLS-VIVIT-GFP vector. One month
later, a cranial window was implanted.
Neurites and spines were detected and
quantified by multiphoton imaging in the
living animal (Fig. 8A). High-
magnification images were taken to visu-
alize dendritic spines. Spine density was
quantified for each neuritic segment using
the NeuronStudio software (see Materials
and Methods). Importantly, no signifi-
cant difference was observed when com-
paring the spine density in wild-type
littermate mice injected with either
AAV-GFP (0.47  0.11 spines/m),
AAV-VIVIT-GFP (0.49  0.107 spines/
m), or AAV-NLS-VIVIT-GFP (0.53 
0.1 spines/m) (data not shown), indicat-
ing that VIVIT-GFP does not have an effect on spine density by
itself, i.e., independently of A.
Compared with dendrites fromGFP-injected wild-type litter-
mates (0.47 0.11 spines/m), dendrites in the vicinity of amy-
loid deposits (100 m away from plaque) in APP/PS1 mice
exhibited a decreased spine density (0.31  0.12 spines/m).
This amyloid-associated spine loss was restored to essentially
normal levels when either AAV-VIVIT-GFP (0.49 0.13 spines/
m) or AAV-NLS-VIVIT-GFPAAV-GFP (0.44  0.1 spines/
m) were injected in APP/PS1 mice (Fig. 8B). In both APP/PS1
animals and human AD brains the spine densities are correlated
with the distance from the edge of the amyloid deposits (correla-
tion coefficient: 0.41) (Koffie et al., 2009) (Spires et al., 2005).
However, this local effect of amyloid plaques was nearly abol-
ished when AAV-NLS-VIVIT-GFP (correlation coefficient:
0.22) or AAV-VIVIT-GFP was expressed (correlation coeffi-
cient: 0.09; Fig. 8C).
Overall, the injection of AAV-VIVIT-GFPwas associatedwith
a marked recovery of spine density around amyloid deposits in
vivo. A significant beneficial effect was also observed in AAV-
NLS-VIVIT injected mice, even though this improvement did
not reach the levels of VIVIT-GFP. This difference might be due
to the fact that some of the GFP-filled neurites observed in ani-
mals coinjected with AAV-NLS-VIVIT-GFP and AAV-GFP had
only been transduced by the later vector. To examine this possi-
bility, we coinjected the AAV-NLS-VIVIT-GFP and an AAV-
TdTomato with the same 3:1 ratio as previously used, and we
observed that 86% of the red fluorescent cells also contained a
nuclear GFP signal (Fig. 7B), suggesting that the vast majority of
transduced neurons expressed both recombinant proteins.
Neuritic abnormalities observed around amyloid deposits
in APP/PS1mice are partially restored by VIVIT-GFP
and NLS-VIVIT-GFP
The presence of amyloid deposits not only affects the density of
dendritic spines, but is also known to disturb themorphology of the
neuritic shaft itself (Knowles et al., 1999). We therefore asked
whether overexpression of VIVIT orNLS-VIVITmight have an ad-
ditional rescue effect in regards to these morphological parameters.
As previously shown, amyloid deposits are associated with the
development of neuritic dystrophies, which can be visualized by
AAV-GFP injection in APP/PS1mice. Even though the size of the
4
(Figure legend continued.) complexity compared with GFP-transfected Tg neurons and
reaches the level of complexity observed inWtneurons.D, Images representativeofDsRed filled
neurons (left) or dendritic segments (right) after co-transfection by GFP, NLS-VIVIT-GFP, or
Myr-VIVIT-GFP and 24 h treatment with WtCM and TgCM. Scale bar, 100m. E, A decreased
spine density was induced by TgCM, which could be inhibited by NLS-VIVIT-GFP but not by
Myr-VIVIT-GFP. *p 0.05, **p 0.001 and ***p 105. (n 40 cells per condition).
Figure7. In vivo, NLS-VIVIT-GFP is targeted to thenucleusandcoinjectionofbothAAV-NLS-VIVIT andAAV-Tdtomatoefficiently
transduces the same cells. A, Representative in vivo images of a mouse injected with AAV-NLS-VIVIT-GFP (left) confirm that the
localization of NLS-VIVIT is restricted to the nucleus and colocalizes with Hoechst applied topically (right). Scale bars: 100m on
the left and 50m on the right. B, Coinjection of AAV-NLS-VIVIT-GFP and AAV-Tdtomato with an appropriate ratio (3:1) is an
efficient approach to be able to detect spines in vivo and to ascertain the fact that the observed Tomato-transduced cells also
express NLS-VIVIT (arrows indicate GFP/Tdtomato double positive cells). Scale bars: 100mon the top and 50mon the bottom.
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amyloid plaques that were analyzed was comparable between all
the injected animals, plaques from AAV-VIVIT-treated mice
were associated with fewer dystrophies (5  4 dystrophies/
plaque) compared with those from AAV-GFP (14  9 dystro-
phies/plaque) and AAV-NLS-VIVIT (18  10 dystrophies/
plaque; Fig. 9A,B) injected mice. Because the density of GFP-
filled neurons around plaques was similar among all the groups
(data not shown), we conclude that the difference in the number
of dystrophies was not due to a decreased amount of GFP-filled
neurites between AAV-GFP and AAV-VIVIT-GFP treated ani-
mals. This finding suggests that dystrophies, unlike dendritic
spine loss, might not be recovered by a restricted inhibition of
NFAT transcriptional activity in the nucleus. Interestingly, like
VIVIT, calcineurin inhibitionwith FK506 led to an improvement
in neuritic dystrophies (Rozkalne et al., 2011). The remaining
dystrophies in AAV-VIVIT-treated mice were similar in size to
those from AAV-GFP and AAV-NLS-VIVIT-injected mice.
A third morphological characteristic of neurites around amy-
loid deposits is a subtle change in their trajectories (Knowles et
al., 1999). This abnormal neuritic curvature was assessed on
paraffin-embedded sections after immunostaining for GFP and
amyloid plaques. The curvature ratio was calculated by reporting
the length of a neurite divided by the end-to-end length of the
same segment.Weobserved that the average neuritic curvature of
both AAV-VIVIT-GFP (1.054  0.038) and AAV-NLS-VIVIT-
GFP (1.059 0.048) injected mice were improved around amy-
Figure8. Spine loss detected in the vicinity of amyloid deposits is significantly improvedbyVIVIT-GFPandNLS-VIVIT-GFP.A, Left, z-projections of two-photon images representative of GFP-filled
neurites in littermate mice injected with AAV-GFP or surrounding amyloid deposits in APP/PS1 mice injected with AAV-GFP, AAV-VIVIT-GFP, and AAV-NLS-VIVIT-GFPAAV-GFP. Right, Pictures
represent an example of dendritic spine detection using theNeuronstudio software. Brown, red, and yellow circles respectively indicatemushroom, stubby, and thin spines. Scale bar, 50m.B, Bar
graph summarizing the averaged spine density of each group confirms that APP/PS1mice injectedwith AAV-VIVIT-GFP and AAV-NLS-VIVIT-GFP have a higher spine density than AAV-GFP injected
Tg animalswithin 100msurrounding amyloid deposits. Spine densities of either VIVIT-GFP or NLS-VIVIT-GFP treated groups are not significantly different fromGFP injected littermates. C, Scatter
plot of spine density data collected from GFP-injected APP/PS1mice show a positive correlation between spine density and distance from amyloid deposit, but this local effect of amyloid plaque is
partially and even completely abolished when animals were treated with NLS-VIVIT-GFP or VIVIT-GFP, respectively. *p 0.05 between AAV-GFP-treated APP/PS1mice and either AAV-VIVIT-GFP
or AAV-NLS-VIVIT-GFP injected animals. (n 6 animals and n 200 dendrites analyzed per condition).
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loid deposits comparedwith AAV-GFP-treated animals (1.081
0.07) (Fig. 9C,D).
The beneficial effects associated with VIVIT-GFP and
NLS-VIVIT-GFP correlate with a decreased recruitment of
NFATc4 into the nucleus
Using an in vivo imaging approach, we observed that several neu-
ronal morphological parameters (i.e., spine density, neuritic dys-
trophies and curvature) that are abnormal in the vicinity of
amyloid deposits were significantly improved when either AAV-
VIVIT-GFP or AAV-NLS-VIVIT-GFP was injected in the cortex
of APP/PS1 mice. To verify that these beneficial effects were related
to the efficient inhibition of NFATc4 recruitment into the nucleus,
we performed a postmortem immunohistological analysis.
Brain sections of injected mice were stained to detect both
GFP and endogenous NFATc4 to determine the ratio of NFATc4
in the nucleus versus cytoplasm in transduced neurons. We
found that the distribution of NFATc4 nuclear/cytoplasmic ra-
tios was shifted toward lower values in APP/PS1 mice injected
with AAV-VIVIT-GFP treated animals (0.8  0.08) compared
with AAV-GFP (0.89  0.06). AAV-NLS-VIVIT-GFP-injected
mice exhibited an intermediate NFATc4 nuclear/cytoplasmic ra-
tio between AAV-GFP and AAV-VIVIT-GFP-injected animals
(0.83 0.09) (Fig. 10A,B).
Discussion
The biological mechanisms that sculpt the fine structure of the
adult brain and their alterations in neurodegenerative diseases
remain largely unknown. In this report we demonstrated that A
neurotoxic damage can be prevented or even reversed by inhib-
iting calcineurin-mediated activation of NFAT. Importantly, the
same profound morphological changes occur when a constitu-
Figure9. OverexpressionofVIVIT-GFPandNLS-VIVIT-GFPpartially improvetheneuriticabnormalities invivo.Representativepictures(A)andquantifications(B)ofdystrophiessurroundingamyloiddeposits
showthat fewerneuritic dystrophies arepresentwhenAAV-VIVIT-GFP is injected, butno improvement canbeobservedwhenNLS-VIVIT-GFP is overexpressed. Scalebar, 50m. (n35amyloidplaques and
n250dystrophies analyzedpergroup).C, Representative imagesofGFPandamyloiddeposits immunostaining inAPP/PS1-injectedmice. Scalebar, 100m.D, InAPP/PS1mice injectedwithAAV-GFP, the
increasedcurvatureratiois inverselycorrelatedwiththedistanceofeachneuritetotheclosestamyloiddeposit(p0.0001,slope-0.0006).Thereis,however,nosuchcorrelationinAPP/PS1micetreatedwith
either VIVIT-GFP (p 0.953, slope-5.12 106) or NLS-VIVIT-GFP (p 0.812, slope 0.00003). *p 0.05. (n 6 animals per group).
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tively active form of the transcription factor NFAT is introduced.
The results are consistent with the hypothesis that the neurotoxic
effects of A are mediated, at least in part, by the transcriptional
activation of NFAT downstream target genes. Although the con-
tribution of NFAT to neurological function or dysfunction has re-
ceived little attention, recent findings have demonstrated a role of
NFAT in synaptic plasticity during development (Nguyen and Di
Giovanni, 2008; Schwartz et al., 2009). Moreover, NFAT shows an
abnormal nuclear accumulation in the brains of ADpatients (Wu et
al., 2010),whichdirectly correlateswith the levels of solubleA(1–42)
and the severity of cognitive impairment (Abdul et al., 2009).
Our study provides evidence supporting the idea that NFAT is
a specific molecular mediator of transcription-dependent
modifications of the CNS structure in the context of Alzhei-
mer’s disease.
In vitro, we observed that the morphological changes induced
by constitutively active calcineurin or by constitutively active
NFAT replicate the decrease of spine den-
sity and dendritic simplification induced
by the neurotoxic A peptides. Along
with recent data indicating that calcineu-
rin is activated both in human AD brain
and in transgenicmodels of AD (Liu et al.,
2005; Dineley et al., 2007;Wu et al., 2010),
we tested the hypothesis that inhibition
of the excessive NFAT activity might im-
prove the neuritic abnormalities observed
in AD models. We demonstrate that VI-
VIT, a genetically encoded inhibitor of the
interaction between calcineurin and
NFAT, increases both the spine density and
the complexity of dendritic arbors in
APPswe-transgenic neurons or in TgCM-
treated wild-type neurons. In vivo, a gene
transfer approach using adeno-associated
vectors enabled the delivery of VIVIT to
neurons and significantly increased the
spine density in the vicinity of senile
plaques. Transduction with an inhibitor
that, due to a nuclear localization signal
(NLS-VIVIT), specifically blocked the nu-
clear activation of NFAT, was also able to
restore to nearly normal the morphological
abnormalities associated with A. The abil-
ity of NLS-VIVIT to reproduce the same
beneficial effects as VIVIT is intriguing, as
this peptide is thought to interact primarily
with the docking site of NFAT upon CaN.
However, several studies demonstrated that
activated CaN is able to translocate to the
nucleus inneurons (Pujol et al., 1993;Sola` et
al., 1999; Yang et al., 2005; Schwartz et al.,
2009), a phenomenon we also previously
described in AD patients (Wu et al., 2010).
We therefore propose that both CaN and
NFAT translocate to the nuclear compart-
ment, where VIVIT would compete with
NFAT for CaN binding. Considering the
higher affinity of VIVIT for CaN [25-fold
compared with NFAT (Aramburu et al.,
1999)], the CaN/NFAT interaction would
thus be interrupted and NFAT would rap-
idly be phosphorylated and shuttled back to
the cytoplasm. This hypothesis is in agreement with the previous
observation that NLS-VIVIT efficiently inhibited the expression of
NFAT-target genes (Schwartz et al., 2009), andwith our observation
of a significant decrease in the NFAT nuclear/cytoplasmic ratio not
only in AAV-VIVIT-GFP-injected animals but also in AAV-NLS-
VIVIT-treatedmice.
Our results indicate that (1) NFAT activation is a likely con-
sequence of A accumulation in Alzheimer’s disease, as sug-
gested by its prominent nuclear localization in the brain of AD
patients (Abdul et al., 2009; Wu et al., 2010), and by the ability of
VIVIT to restore A-associated morphological neurodegenera-
tive changes; (2) once activated and translocated to the nucleus,
NFAT presumably induces the transcription of target genes in
mature neurons that lead to a pathological remodeling of den-
drites and dendritic spines. The beneficial effect of a nucleus-
directed NFAT inhibitor supports the role of transcriptional
events in the regulation of dendritic spine stability in vitro and in
Figure 10. Overexpression of VIVIT-GFP and NLS-VIVIT-GFP prevent NFATc4 accumulation in the nucleus of transduced neu-
rons. A, Representative images of GFP immunostaining and endogenous NFATc4 in injected animals allows detection of endoge-
nousNFATc4 in transducedneurons. Scalebar, 50m; for highermagnification images, on the right, 20m.Highermagnification
images ofNFATc4 andDAPI (third column) show that an increased recruitment ofNFATc4 is detected inAAV-GFP-injectedAPP/PS1
mice. B, The ratios of NFATc4 immunofluorescence intensity between the nucleus and the cytoplasm follow a normal distribution
in all three groups tested. However, there is a shift toward higher values in AAV-GFP-injected APP/PS1 mice compared with
AAV-VIVIT and AAV-NLS-VIVIT treated animals. On the graph, the blue line represents the mean of NFATc4 nuclear/cytoplasmic
ratio in AAV-GFP injected APP/PS1 mice. The nuclear/cytoplasmic ratio is significantly increased in AAV-GFP treated transgenic
mice compared with AAV-VIVIT-GFP and AAV-NLS-VIVIT-GFP ( p 0.05). (n 4 animals per group and 3 slices per animal were
analyzed).
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vivo. To some extent, these findings are unexpected, as the mod-
ulation of spine morphology has been largely focused on endo-
cytosis and stability of AMPAR and NMDAR receptors, rather
than transcriptionally regulated phenomena (Lau and Zukin,
2007; Zhang et al., 2008; Bhattacharyya et al., 2009; Goebel-
Goody et al., 2009). Although local spine-specific phenomena
will ultimately determine the stability of individual spines, the
current data emphasize that dendritic trees and spine density are
also impacted at a transcriptional level. This conclusion is in
accordance with a growing literature suggesting that transcriptional
modulation can affect memory function (Saura and Valero, 2011),
and with recent data demonstrating that alterations in mRNA traf-
ficking and stability can lead to neural system alterations and degen-
eration in disorders as disparate as autism and amyotrophic lateral
sclerosis (Gatto and Broadie, 2010).
The literature addressing the question of NFAT target genes
specifically regulated in neurons is quite limited, but few inter-
esting findings might be relevant in the context of Alzheimer’s
disease. For example, NFAT was shown to contribute to the in-
duction of apoptosis in neuroblastoma cells through upregula-
tion of Fas Ligand (Fas-L) (Luoma andZirpel, 2008; Alvarez et al.,
2011), a gene that was also reported to increase in AD brains,
especially in the hippocampal formation and entorhinal cortex
that are primarily involved inmemory encoding. In addition, A
peptides induce a pathological increase in Fas-L in cortical pri-
mary neurons and its accumulationwas demonstrated in neuritic
dystrophies surrounding the amyloid deposits (Su et al., 2003).
Even though no direct connection between Fas-L and spinemor-
phology has been reported so far, one of the down-stream target
of Fas-L, capsase-3, was recently shown to trigger early synaptic
dysfunction and spine loss in AD (D’Amelio et al., 2011). This
would suggest that activation of caspase-3 may not only be in-
volved in cell death but is also closely associated with the regula-
tion of synaptic plasticity. It is therefore possible that the
activation of Fas-L expression by NFAT indirectly causes a syn-
aptic failure via the induction of a non-apoptotic caspase-3 path-
way. The expression of the potassium channel Kv2.1 can also be
driven by NFAT and was shown to be upregulated by 72% in the
hippocampus of rat injected with A25–35. (Pan et al., 2004). In-
terestingly, the use of several potassium channel openers (mi-
noxidil, pinacidil, cromakalim) can induce amnesia in mice
(Ghelardini et al., 1998), thus suggesting that the regulation of the
activity of the potassium channels might impair memory encod-
ing, one of the best hallmark of AD. As learning and memory
deficits mainly reflect a default in spine-mediated plasticity, we
can hypothesize that dysregulation of the potassium channel
Kv2.1might lead to the alteration of dendritic spinemorphology.
Last, the upregulation of the inositol 1,4,5-trisphosphate type 1
receptor (InsP3R) gene by NFAT is of particular interest in the
context of Alzheimer’s disease (Genazzani et al., 1999; Amberg et
al., 2004). Indeed, InsP3R was shown to directly interact with
presenilins 1 and 2, increasing its activity in response to Inositol-
3-phosphate, thus leading to an excessive release of Ca2 (Mu¨ller
et al., 2011). The upregulation of InsP3R might therefore partic-
ipate to exacerbate the increase of the resting calcium levels. The
few examplesmentioned abovemight be of interest in the context
of AD, but other NFAT target genes previously identified does
not seem relevant in a pathological context. Indeed, NFAT tran-
scriptional activity was associatedwith an increased expression of
the neurotrophic factor BDNF in Purkinje cells, an important
mediator of axonal outgrowth during development (Graef et al.,
2003). These varied results could be explained by the ability of
NFAT to interact with other transcriptional factors (Crabtree and
Olson, 2002; Ogata et al., 2003; Kao et al., 2009), a mechanism by
which the pattern of NFAT-induced target genes can be modu-
lated depending on the developmental state, on the cell type, and
on the physiological or pathological context. It is therefore con-
ceivable that a particular set of NFAT coactivators are present in
cortical neurons exposed to A, so that its activation leads to the
upregulation of genes implicated in dendritic spine shrinkage.
Although the transcriptional effects of NFAT (and its inhibi-
tion) await further investigation, the present study provides a
novel neuroprotective therapeutic target against the downstream
neurotoxic effects of amyloid- and confirms the feasibility to
pharmacologically arrest the “amyloid cascade” of neurodegen-
eration at a step after amyloid deposition has already occurred.
The latter has critical therapeutic implications, since most amy-
loid deposition is thought to occur years or even decades before
the onset of cognitive decline, and therefore, before AD diagno-
sis, whereas synaptic and neuron loss largely occurs in a second
stage and correlates with the severity of cognitive impairment
(Sperling et al., 2009). In this scenario, amyloid-directed thera-
pies would not be sufficiently effective once cognitive symptoms
(and the underlying neurodegenerative processes) have begun.
Consequently, combined synergistic therapies aimed at reducing
A content (either by inhibiting the production ofApeptides or
by increasing their clearance) and at restoringA-induced neural
damage would be needed.
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